KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) Research & Development: 2018-2025

Historic Research & Development for Castle Biosciences (CSTL) over the last 8 years, with Sep 2025 value amounting to $13.0 million.

  • Castle Biosciences' Research & Development rose 5.17% to $13.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.1 million, marking a year-over-year decrease of 5.92%. This contributed to the annual value of $52.0 million for FY2024, which is 2.94% down from last year.
  • Per Castle Biosciences' latest filing, its Research & Development stood at $13.0 million for Q3 2025, which was up 1.35% from $12.8 million recorded in Q2 2025.
  • In the past 5 years, Castle Biosciences' Research & Development ranged from a high of $14.4 million in Q1 2023 and a low of $5.9 million during Q1 2021.
  • For the 3-year period, Castle Biosciences' Research & Development averaged around $13.1 million, with its median value being $13.0 million (2025).
  • In the last 5 years, Castle Biosciences' Research & Development soared by 151.22% in 2021 and then fell by 9.54% in 2025.
  • Quarterly analysis of 5 years shows Castle Biosciences' Research & Development stood at $9.4 million in 2021, then climbed by 19.74% to $11.3 million in 2022, then rose by 14.90% to $13.0 million in 2023, then declined by 9.40% to $11.8 million in 2024, then climbed by 5.17% to $13.0 million in 2025.
  • Its Research & Development was $13.0 million in Q3 2025, compared to $12.8 million in Q2 2025 and $12.6 million in Q1 2025.